ICMR, Panacea Biotec initiate 1st dengue vaccine Phase 3 clinical trial
This landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec, it said.
This landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec, it said.
